Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1
Graphical abstract
Introduction
Cancer, known medically as malignant neoplasm or tumor, is the second most leading cause of death after cardiovascular disease in the United States and developing countries [1]. Cancer treatment is often consisted of surgery, radiation therapy, chemotherapy and combination therapy. Chemotherapy has been the first-line approach for the treatment of most cancers for several decades, and it typically involves systemic administration of combination of anticancer drugs from different chemical groups with different mechanism of action and depends on the capability of highly cytotoxic drugs to penetrate and selectively kill cancer cells [2]. However, cancer cells often exhibit either intrinsic or acquired resistance to chemotherapy through a phenomenon known as multidrug resistance (MDR) [3]. Many factors are responsible for the development of MDR, preeminent among them is the accelerated drug efflux mediated by overexpression of ATP binding cassette (ABC) transporters [4]. These ABC transporters serve as a defense mechanism by pumping harmful substrates out of normal cells. In a similar manner, cancer cells tend to overexpress these transporters in order to protect themselves from cytotoxic anticancer drugs. These transporters efflux drugs by consuming the energy produced via hydrolysis of ATP [5]. So far, 48 human ABC transporters have been identified and categorized into seven subfamilies, from ABCA to ABCG, based on structural and sequence similarities [6]. Among them, ABCB1, ABCG2, and ABCCs are the primary contributors of MDR in cancer cells [7].
ABCB1, also called P-glycoprotein encoded by MDR1 gene, was the first discovered mammalian ABC transporter [8], [9]. It is comprised of two homologous halves, each containing six transmembrane helices and an ATP binding/utilization domain, separated by a flexible linker. ABCB1 is a 170-kDa apical plasma membrane protein ubiquitously expressed in kidney, placenta, liver, adrenal glands, intestine and blood-brain barrier cells, where it functions to protect against xenobiotics and cellular toxicants [10], [11]. In addition, ABCB1 can transport a wide range of anticancer drugs such as doxorubicin, vincristine, paclitaxel, and epipodophyllotoxins out of the cancer cells [7], [12]. The overexpression of ABCB1 can be induced after repeated exposure to anticancer drugs, when the tumor becomes refractory to chemotherapy. ABCG2, a 72-kDa protein, is the first known half transporter with only one nucleotide binding domain and one transmembrane domain to mediate MDR [13]. The functional unit of ABCG2 is a homodimer or an oligomer [14]. The wide spectrum of chemotherapeutic agents transported by ABCG2 ranges from organic anion conjugates, nucleoside analogues, organic dyes, tyrosine kinase inhibitors (TKIs) to anthracyclines (such as doxorubicin, mitoxantrone), camptothecin-derived indolocarbazole topoisomerase I inhibitors, methotrexate, and flavopiridols [14]. ABCC1 (MRP1), which is a member of the C subfamily of ABC transporters can also transport various hydrophobic drugs; some anionic drugs and its drug conjugates, including antifolates, certain nucleotides, and also vinca alkaloids [15], [16]. ABCC10, also known as multidrug resistance protein 7 (MRP7), is a 171-kDa protein that can transport various anticancer drugs, including docetaxel, paclitaxel, vincristine, vinblastine, cytarabine, gemcitabine and epothilone B [17], [18].
In the last three decades, MDR research has mainly focused on developing inhibitors of ABC transporters, which have minimal toxicity in normal cells. It has been reported that some epidermal growth factor receptor (EGFR) TKI inhibitors including AG1478, erlotinib and lapatinib significantly reversed ABCB1- and ABCG2-mediated MDR, indicating that these TKIs might be modulators of ABCB1 and ABCG2 transporters [19]. In addition, BCR-Abl TKIs (imatinib and nilotinib) were also found to reverse ABCB1-and ABCG2-mediated MDR [20]. An in vivo study using the combination of gefitinib and a camptothecin derivative has shown a better pharmacokinetic profile and anti-tumor activity compared to camptothecin derivatives alone [21]. Our lab has also reported that the anti-tumor response to paclitaxel was enhanced by lapatinib in ABCB1 overexpressing nude mice tumor xenografts [22]. Moreover, erlotinib, lapatinib, imatinib, and nilotinib significantly reverse ABCC10-mediated MDR [23], [24]. Canertinib (CI-1033), a human epidermal receptor (HER) TKI, was found to reverse ABCG2-mediated MDR in cancer cells [25]. Some multikinase TKIs (such as sunitinib) have shown a reversal activity in both ABCB1- and ABCG2-mediated MDR [26], [27]. All these in vitro and in vivo studies reveal that the combination therapy of TKIs and conventional chemotherapeutic drugs could significantly sensitize MDR cells that overexpress diverse ABC transporters. Therefore, given the studies showing that TKIs play a significant role in reversing MDR in cancer cells, it is important to understand their mechanism of action.
Motesanib (AMG706), a novel nicotinamide derivative, was identified as a potent, orally bioavailable inhibitor of the vascular endothelial growth factor receptor 1 (VEGFR1/Flt1), VEGFR2/kinase domain receptor/Flk-1, VEGFR3/Flt4, platelet-derived growth factor receptor (PDGFR) and Kit receptors in preclinical models (Fig. 1A) [28]. In preclinical studies, motesanib induced significant tumor regression in xenograft models of human breast carcinoma [29], non-small cell lung cancer, medullary thyroid cancer, and epidermoid and colon carcinoma [30]. Motesanib is currently under Phase II and Phase III clinical trials for advanced gastrointestinal stromal tumor (GIST), fallopian tube cancer, ovarian cancer, thyroid cancer, non-small cell lung cancer (NSCLC) (www.clinicaltrials.gov). For instance, in the study of patients with imatinib-resistant GIST, motesanib treatment has shown acceptable tolerability and modest tumor control as evident in the proportion of patients who achieved stable disease and durable stable disease [31]. In addition, motesanib can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive. However, a broader applicability of motesanib treatment that inhibits angiogenesis in thyroid cancer needs to be established in further studies [32]. The most common side effects of motesanib treatment were diarrhea, fatigue, hypothyroidism, hypertension and anorexia [33]. The analysis of the phase III MONET1 study demonstrated that motesanib combined with carboplatin/paclitaxel could improve overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared with chemotherapy alone, in a subset of Asian patients with nonsquamous NSCLC [34]. Importantly, the overexpression of ABCB1 has been associated with various cancers, such as GIST, NSCLC, fallopian tube, ovarian and thyroid cancer [35], [36], [37], [38], [39]. It is conceivable that motesanib probably could inhibit the function of ABC transporters by binding to their drug-binding sites as has been found for other TKIs [19]. This has triggered our efforts to determine if motesanib could reverse MDR, which is associated with the overexpression of ABCB1, ABCG2, ABCC1 and ABCC10.
Section snippets
Chemicals and equipment
[3H]-paclitaxel (23 Ci/mmol) was purchased from Moravek Biochemicals, Inc. (Brea, CA). Dulbecco's modified Eagle's medium (DMEM), RPMI-1640 medium, fetal bovine serum (FBS), penicillin/streptomycin and trypsin 0.25% were products of Hyclone, Thermo Scientific (Logan, UT). The monoclonal antibodies BXP-21 (against ABCG2), sc-47778 (against β-Actin) and the secondary horseradish peroxidase-labeled rabbit anti-mouse IgG were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). The monoclonal
Effect of motesanib on ABCB1 substrates in cell lines overexpressing ABCB1
In order to select a non-toxic drug concentration for motesanib, cytotoxicity assays were performed on the cell lines (Fig. 1B and C). Based on these results, concentrations of 1 μM and 3 μM were chosen, because more than 85% of the cells survived at 3 μM. In order to determine whether motesanib could reverse ABCB1-mediated MDR, cell survival assays were performed in the presence and absence of motesanib, using the parental KB-3-1 cell line and drug selective KB-C2 cell line. The drug selective
Discussion
ABCB1/P-gp developed as such an essential MDR transporter along with some relatively novel transporters (like ABCG2, ABCC1 and ABCC10) family for several major chemotherapeutic drugs. Widespread expression of ABCB1 and ABCG2 in prominent body organs has not only protective function against some xenobiotics and pharmacological compounds, but also affects the pharmacokinetics of some substrate chemotherapeutic drugs [56]. Development of TKIs in recent years has marked a therapeutic breakthrough
Conflicts of interest
There are no conflicts of interest.
Grant support
This work was supported by funds from NIH (No. 1R15CA143701), Ray Biotech Inc. and St. John's University Research Seed Grant (No. 579-1110-7002) to Z.S. Chen. Drs. SS, KLF and SVA were supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.
Acknowledgements
We thank Drs. Shinichi Akiyama (Kagoshima University, Japan) for the KB-C2 cell lines, Susan E. Bates and Robert W. Robey (NIH, USA) for the FTC compound, NCI-H460, and NCI-H460/MX20 cell lines. We thank Dr. Stephen Aller (The University of Alabama at Birmingham, Birmingham, US) for providing human ABCB1 homology model. We also thank Dr. Michael M. Gottesman (NCI, NIH, USA) for carefully reading and editing the manuscript.
References (64)
- et al.
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Biochim Biophys Acta
(1976) - et al.
Multidrug resistance and the role of P-glycoprotein knockout mice
Eur J Cancer
(1995) STI-571: an anticancer protein-tyrosine kinase inhibitor
Biochem Biophys Res Commun
(2003)- et al.
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Drug Resist Updat
(2012) - et al.
Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
Biochem Pharmacol
(2009) - et al.
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
Drug Resist Updat
(2005) - et al.
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance
Biochem Pharmacol
(2010) - et al.
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
Cancer Lett
(2009) - et al.
Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis
Ann Oncol
(2014) - et al.
AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance
Cancer Lett
(2014)
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance
Biochem Pharmacol
Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells
Methods Enzymol
Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance
Biochem Pharmacol
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
CA: Cancer J Clin
Cancer statistics
CA: Cancer J Clin
Mechanisms of cancer drug resistance
Annu Rev Med
Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs
Adv Exp Med Biol
Complete characterization of the human ABC gene family
J Bioenerg Biomembr
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins
Physiol Rev
Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates
Annu Rev Genomics Hum Genet
Multidrug resistance in cancer: role of ATP-dependent transporters
Nat Rev Cancer
Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system
Physiol Rev
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
J Cell Sci
Role of the breast cancer resistance protein (ABCG2) in drug transport
AAPS J
The MRP family of drug efflux pumps
Oncogene
Multidrug resistance associated proteins in multidrug resistance
Chin J Cancer
Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(−/−) mice
Cancer Res
Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs
Chin J Cancer
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
Cancer Res
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10)
PLoS ONE
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
Cancer Res
Sunitinib, (Sutent SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2
Drug Metab Dispos
Cited by (53)
Targeted therapy and drug resistance in thyroid cancer
2022, European Journal of Medicinal ChemistryCitation Excerpt :Inhibiting ABC transporters may augment drug efficacy to a certain degree, and the main mechanism of ABC transporter inhibitors is to act as substrate competitors with anticancer drugs [35]. Motesanib, with a potential antitumor effect on thyroid cancer, can block the efflux activity of the ABCB1 transporter in vitro and thus contribute to the accumulation of paclitaxel in the KB-C2 cell line overexpressing ABCB1 [113]. Cabozantinib 4, as a competitive ABCG2 substrate [36], can reverse MDR by blocking the efflux of ABCG2 rather than decreasing ABCG2 protein expression in MTC.
Synthesis of indoles, indolines, and carbazoles via palladium-catalyzed C–H activation
2021, Green Synthesis and CatalysisCitation Excerpt :The same group later showed that the diaziridinone reagent can react with pallada(II)cycles generated from C(sp3)–H activation with a proximal alkyl group (Scheme 23a) [46]. Notably, 3,3-dimethylindoline structures are attractive scaffolds in the drug discovery process [47] and can easily be accessed by using this method. A study of the stoichiometric palladacycle showed that the phosphine ligand was necessary to promote the amination process, as the desired indoline product could not be obtained when 1,5-cyclooctadiene (COD) was used as the sole ligand (Scheme 23b).
Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells
2019, Bioorganic and Medicinal ChemistryCitation Excerpt :After washing for another three times, proteins were visualized using the enhanced chemiluminescence detection system and Quantity One software were used to analyses the protein’s band intensity35,36.
Design, synthesis and biological evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide derivatives as novel P-glycoprotein inhibitors reversing multidrug resistance
2019, Bioorganic ChemistryCitation Excerpt :Hence, discovery of novel P-gp inhibitors having high efficiency and safety is extremely urgent. Studies have shown that several tyrosine kinase inhibitors (TKIs) having the structure of quinazoline can effectively inhibit P-gp activity [12,13]. Our group have designed, synthesized and evaluated novel quinazoline P-gp inhibitors.